Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iohexol
Drug ID BADD_D01180
Description Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Indications and Usage Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Marketing Status approved
ATC Code V08AB02
DrugBank ID DB01362
KEGG ID D01817
MeSH ID D007472
PubChem ID 3730
TTD Drug ID D02BLO
NDC Product Code 43228-100; 0407-1413; 71806-141; 0407-1414; 0407-1416; 0407-1415; 0407-1401; 0407-1411; 0407-1412; 65072-0801; 54702-501
UNII 4419T9MX03
Synonyms Iohexol | Iohexol 350 | Nycodenz | Compound 545 | Exypaque | Omnipaque
Chemical Information
Molecular Formula C19H26I3N3O9
CAS Registry Number 66108-95-0
SMILES CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Slow response to stimuli17.02.05.0630.007113%Not Available
Aneurysm ruptured24.02.01.0020.056907%Not Available
Iodine allergy10.01.01.0160.007113%Not Available
Laryngeal discomfort22.12.03.0090.017783%Not Available
Communication disorder19.19.01.0080.007113%Not Available
Foaming at mouth07.05.05.019; 17.02.05.056; 08.01.03.0700.017783%Not Available
Fear of death19.06.03.0060.014227%Not Available
Oral mucosal erythema07.05.05.023--Not Available
Skin plaque23.03.03.044--Not Available
Tongue pruritus07.14.02.0210.039124%Not Available
Lip pruritus07.05.05.0210.015649%Not Available
Hyporesponsive to stimuli17.02.05.0570.019206%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.007113%Not Available
Palatal swelling07.05.04.009--Not Available
Disorganised speech19.19.02.005; 17.02.08.0170.010670%Not Available
Pharyngeal paraesthesia22.04.05.018; 17.02.06.0350.024186%Not Available
Vein rupture24.03.02.032; 12.01.11.0110.007113%Not Available
Contrast media allergy10.01.01.010; 12.02.05.0160.624555%Not Available
Fixed eruption23.03.05.008; 10.01.01.037; 08.01.06.0250.015649%Not Available
Gait inability17.02.05.069; 08.01.02.0110.049794%Not Available
Graves' disease10.04.08.014; 06.09.04.009; 05.02.02.0090.007113%Not Available
Intravascular gas24.03.02.037; 12.01.08.0480.029876%Not Available
Laryngeal obstruction22.04.02.0090.007113%
Larynx irritation22.04.01.0150.014227%Not Available
No reaction on previous exposure to drug08.06.01.042--Not Available
Periorbital swelling23.04.01.025; 10.01.05.025; 06.08.03.0320.019206%Not Available
Pharyngeal swelling22.04.05.0280.039124%Not Available
Swelling of eyelid23.04.01.026; 10.01.05.026; 06.04.04.0180.007113%Not Available
Throat clearing22.12.03.028--Not Available
Urticaria papular23.04.02.019; 10.01.06.0190.017783%Not Available
The 13th Page    First    Pre   13    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene